Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$47.75 USD
+1.14 (2.45%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $47.72 -0.03 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AGIO 47.75 +1.14(2.45%)
Will AGIO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGIO
Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains?
Prestige Consumer Healthcare (PBH) Down 0.4% Since Last Earnings Report: Can It Rebound?
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
Are Medical Stocks Lagging Lantheus (LNTH) This Year?
Other News for AGIO
Agios Pharma (AGIO) Receives a Buy from Piper Sandler
Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024
Small-cap, buy-rated stocks with positive estimate revision factors - BofA
JPMorgan biotech analysts hold an analyst/industry conference call
Expert Ratings For Agios Pharmaceuticals